Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev












Signal Accounts for Members
All Signal Accounts
All Contests



Turkey Trade BalanceA:--
F: --
P: --
Germany Construction PMI (SA) (Nov)A:--
F: --
P: --
Euro Zone IHS Markit Construction PMI (Nov)A:--
F: --
P: --
Italy IHS Markit Construction PMI (Nov)A:--
F: --
P: --
U.K. Markit/CIPS Construction PMI (Nov)A:--
F: --
P: --
France 10-Year OAT Auction Avg. YieldA:--
F: --
P: --
Euro Zone Retail Sales MoM (Oct)A:--
F: --
P: --
Euro Zone Retail Sales YoY (Oct)A:--
F: --
P: --
Brazil GDP YoY (Q3)A:--
F: --
P: --
U.S. Challenger Job Cuts (Nov)A:--
F: --
P: --
U.S. Challenger Job Cuts MoM (Nov)A:--
F: --
P: --
U.S. Challenger Job Cuts YoY (Nov)A:--
F: --
P: --
U.S. Initial Jobless Claims 4-Week Avg. (SA)A:--
F: --
P: --
U.S. Weekly Initial Jobless Claims (SA)A:--
F: --
P: --
U.S. Weekly Continued Jobless Claims (SA)A:--
F: --
P: --
Canada Ivey PMI (SA) (Nov)A:--
F: --
P: --
Canada Ivey PMI (Not SA) (Nov)A:--
F: --
P: --
U.S. Non-Defense Capital Durable Goods Orders Revised MoM (Excl. Aircraft) (SA) (Sept)A:--
F: --
U.S. Factory Orders MoM (Excl. Transport) (Sept)A:--
F: --
P: --
U.S. Factory Orders MoM (Sept)A:--
F: --
P: --
U.S. Factory Orders MoM (Excl. Defense) (Sept)A:--
F: --
P: --
U.S. EIA Weekly Natural Gas Stocks ChangeA:--
F: --
P: --
Saudi Arabia Crude Oil ProductionA:--
F: --
P: --
U.S. Weekly Treasuries Held by Foreign Central BanksA:--
F: --
P: --
Japan Foreign Exchange Reserves (Nov)A:--
F: --
P: --
India Repo RateA:--
F: --
P: --
India Benchmark Interest RateA:--
F: --
P: --
India Reverse Repo RateA:--
F: --
P: --
India Cash Reserve Ratio--
F: --
P: --
Japan Leading Indicators Prelim (Oct)A:--
F: --
P: --
U.K. Halifax House Price Index YoY (SA) (Nov)--
F: --
P: --
U.K. Halifax House Price Index MoM (SA) (Nov)--
F: --
P: --
France Current Account (Not SA) (Oct)--
F: --
P: --
France Trade Balance (SA) (Oct)--
F: --
P: --
France Industrial Output MoM (SA) (Oct)--
F: --
P: --
Italy Retail Sales MoM (SA) (Oct)--
F: --
P: --
Euro Zone Employment YoY (SA) (Q3)--
F: --
P: --
Euro Zone GDP Final YoY (Q3)--
F: --
P: --
Euro Zone GDP Final QoQ (Q3)--
F: --
P: --
Euro Zone Employment Final QoQ (SA) (Q3)--
F: --
P: --
Euro Zone Employment Final (SA) (Q3)--
F: --
Brazil PPI MoM (Oct)--
F: --
P: --
Mexico Consumer Confidence Index (Nov)--
F: --
P: --
Canada Unemployment Rate (SA) (Nov)--
F: --
P: --
Canada Labor Force Participation Rate (SA) (Nov)--
F: --
P: --
Canada Employment (SA) (Nov)--
F: --
P: --
Canada Part-Time Employment (SA) (Nov)--
F: --
P: --
Canada Full-time Employment (SA) (Nov)--
F: --
P: --
U.S. Dallas Fed PCE Price Index YoY (Sept)--
F: --
P: --
U.S. PCE Price Index YoY (SA) (Sept)--
F: --
P: --
U.S. PCE Price Index MoM (Sept)--
F: --
P: --
U.S. Personal Outlays MoM (SA) (Sept)--
F: --
P: --
U.S. Core PCE Price Index MoM (Sept)--
F: --
P: --
U.S. UMich 5-Year-Ahead Inflation Expectations Prelim YoY (Dec)--
F: --
P: --
U.S. Core PCE Price Index YoY (Sept)--
F: --
P: --
U.S. 5-10 Year-Ahead Inflation Expectations (Dec)--
F: --
P: --
U.S. UMich Current Economic Conditions Index Prelim (Dec)--
F: --
P: --
U.S. UMich Consumer Sentiment Index Prelim (Dec)--
F: --
P: --
U.S. UMich 1-Year-Ahead Inflation Expectations Prelim (Dec)--
F: --
P: --
U.S. UMich Consumer Expectations Index Prelim (Dec)--
F: --
P: --


No matching data
Latest Views
Latest Views
Trending Topics
Top Columnists
Latest Update
White Label
Data API
Web Plug-ins
Affiliate Program
View All

No data
Bitcoin down nearly 30% from peak; Mood is turning quickly, traders say; $1.2 trillion wiped off value of crypto since October 7.
A US congressional commission is ringing alarm bells about China's growing dominance over America's drug supply, saying it is putting the country's health in the hands of an adversarial nation.
Roughly one-in-four generic drugs taken by Americans rely on key ingredients from China, according to a report released Tuesday by the US-China Economic and Security Review Commission. The often low-cost staples account for 90% of the medicines used by Americans. Some of the ingredients — found in blood thinners, antibiotics and cancer treatments — are produced only in China.
With China's recent restrictions on rare earth minerals top of mind, the commission said that similar moves involving drug ingredients "could have drastic consequences for the US healthcare system, causing supply shocks that would result in loss of lives and force hospitals to make tough choices in allocating insufficient supply."
Congress formed the commission in 2000 to track the national security implications of the relationship between the US and China. As the group's staff researched the pharmaceutical supply chain, one of the most alarming findings was that the full extent of China's role in making American medicine was unclear, said commission member Leland Miller. He's also the founder and chief executive officer of China Beige Book, a data company that tracks the Chinese economy.
"Forget establishing smart policies; we have not figured out how big the vulnerability is," Miller said. "And we have not figured out how big the vulnerability is because we are unable to secure the data. The government doesn't have the authority to collect the data."
Much of the government's understanding of China's reach is an estimate because the Food and Drug Administration doesn't collect data on where the basic building blocks of medicine are made. The group is recommending Congress prepare legislation that would require companies to disclose that information to the FDA.
"We're really, really far away from figuring this out," Miller said.
Even as its control over generic drugs draws criticism, China is working to replicate that success in the production of more innovative treatments, according to the report. Economic incentives and a more lax regulatory landscape have made China an important development partner for brand-name pharmaceutical companies around the world, particularly for conducting "cheap, fast early-stage exploration," the report said.
A survey last year by the Biotechnology Innovation Organization, an industry trade group, found 79% of 124 biopharmaceutical companies had China-based development and manufacturing partners. Most biotech companies don't have the money needed to make drugs in the US, a key priority for President Donald Trump.
FDA Commissioner Martin Makary floated the idea last month of lowering the multimillion-dollar fees companies are charged for reviewing new medications if early-stage studies are done in the US, rather than in China. Makary told a gathering of pharmaceutical supply chain experts in Washington that the agency is eyeing upcoming user fee negotiations with the industry that occur every five years to negotiate the potentially lower prices.
The Senate report comes as US biotech companies are facing more competition from China.
They're losing out as drugmakers increasingly license experimental medicines from China, particularly new cancer treatments, though the Trump administration is considering a draft executive order to crack down on such deals. Meanwhile, the US Senate passed a measure as part of a military spending bill last month to restrict the US government from using certain Chinese companies involved in the drug supply chain. A final version negotiated with the House is expected later this month.
China isn't done yet. According to the report, it is leading in so-called "synthetic biology," or the artificial creation of biological organisms.
Dominance in that scientific field puts China in an indispensable position on a number of medical fronts, from making amino acids crucial to insulin and antibiotics to developing mRNA technologies and genetically engineered cells. Importantly, it also entrenches the country in every aspect of pharmaceutical production.
"The Chinese synthetic biology industry, for the foreseeable future, will have access to the innovations and know how of global competitors," the report said.
China isn't the only country the US relies on for its drug supply. India also plays a large role, producing the bulk of the country's generic drugs in finished form. While India makes many of the key pharmaceutical ingredients itself, a large share of the necessary materials come from China, according to the report. Also affected are brand-name drugs from Europe, where companies get more than half of their key ingredients from China, the report said.
Many manufacturing plants in China and India have struggled to meet US standards. They are often cited by FDA inspectors for not adhering to manufacturing practices meant to ensure the safety and quality of medications.
In the end, fixing supply chain vulnerabilities will require a wholesale approach, take years and be difficult to pull off, the authors of the report said. It will require "significant modifications to US and global economic statecraft, tools, and approaches," including efforts to bolster domestic manufacturing, they said.
While the Trump administration has secured commitments from some large drugmakers to open manufacturing plants in the US, they don't include generic companies that can't afford it. Recently imposed restrictions and reductions in research funding at US universities and other institutions also could limit America's chances at extracting itself from China's grasp.
Underwriters and brokers with four to six years of experience are commanding higher salaries due to a relative lack of employees at that level, London market recruitment firms told The Insurer.
"Everyone's looking for that experience," said George Matthews, senior consultant at HFG Insurance Recruitment, "someone that can bring knowledge back to the business … and they can hit the ground running."
The lack of people at this level, Matthews said, is because of the time they would have entered the industry, during the COVID-19 pandemic. "In COVID, it was really hard to do these grad schools (and) training programmes … There's a low proportion of people that were trained up and therefore people that made it into the industry."
These hiring reductions affected a market that had already been described as having an ageing workforce, with the London Market Group highlighting as far back as 2014 that more young workers would be needed to build a sustainable talent pipeline.
"When I'm speaking to hiring managers … what they're saying to me is, 'George, I'm hearing about the salaries (people in their 20s) are on … it's crazy the numbers they're asking for.' And this salary they're asking for, the bonus they're asking for, is way over the experience they give to the company," Matthews said. "But guess what, they can ask for it because of a lack of (supply of) talent."
Matthews added that once young employees hear about the salaries their peers have achieved by moving, more are encouraged to change jobs.
Alongside the pandemic, outside investment in the London market and M&A have also contributed to salaries increasing in recent years, said Thomas Cubitt, executive director at recruitment firm Bruin Financial.
"You've got the old school, who've been in the market since the nineties (or) the noughties, who really had to fight (for) a standard 3% pay rise," Cubitt said. "And now this new generation is seeing 20,000(-pound) hikes from 40,000 to 60,000, from 60,000 to 100,000, from 100,000 to 140,000, and they're still in their 30s. And that's to them the norm."
Insurer Ecclesiastical published research in January that found 64% of UK brokers said recruiting young talent was a strategic challenge for their business. Half of brokers struggle to recruit those aged under 30, with two-thirds citing not enough young people applying for available jobs and half stating that applicants didn't have the experience needed.
While these supply-demand dynamics empower employees with five years of experience to negotiate higher salaries, remuneration is not always their only concern. "Some companies do have deep pockets and they're able to throw more money at the person, but other companies have more flexibility: working from home, for instance," said Matthews.
"And then some people go for the brand. There are some companies that they're such massive beasts and they might not pay the same salaries as these mid-tier companies, but because they have the brand and that reputation, it's another good thing to have on the CV."
This week, we are examining challenges related to talent in the London market. Look out for more interviews and analysis on the dynamics at different levels and specialisms within the market, and catch up on yesterday's article focused on the talent shortage at entry level.

The fintechzoom.com bitcoin price page is one of the most referenced sources for quick BTC updates, but understanding today’s price requires looking beyond real-time data. This analysis reviews the past five years of Bitcoin’s market behavior and uses those patterns to build clearer, more realistic predictions for 2025–2026.
FintechZoom aggregates Bitcoin pricing data from multiple market feeds, allowing users to check a near real-time snapshot of BTC trends. While it is not an exchange-based data provider, its blended sources help reflect broader market sentiment rather than a single trading venue’s liquidity conditions.
To give users a quick overview, the fintechzoom.com bitcoin price today page typically updates every few seconds and includes:
For readers seeking a simplified view rather than a deep technical chart, the fintechzoom.com bitcoin price live feed offers a balanced snapshot of the market approach.
The sections below compare FintechZoom to two of the most commonly referenced data platforms. This helps clarify what type of user benefits most from each service.
| Feature | FintechZoom | CoinMarketCap | Binance |
|---|---|---|---|
| Price Update Speed | Fast, every few seconds | Very fast, exchange-aggregated | Real-time (exchange spot price) |
| Charting Tools | Basic trend visuals, simplified signals | Full charting options | Advanced charts with order book depth |
| News Integration | Strong — headlines, macro events, catalysts | Moderate — general market news | Limited — focuses on trading environment |
Many readers use FintechZoom when they want quick explanations about price drivers rather than deep technical indicators. This is why searches such as fintechzoom.com bitcoin price today news tend to land on these sections during periods of volatility or major macro announcements.
FintechZoom's price page is particularly useful for readers who want to understand narratives behind short-term BTC movements. Its strengths include:
Limitations also exist, especially for professional traders:
Overall, the fintechzoom com bitcoin stock price and fintechzoom.com bitcoin price live pages work best for users who want fast interpretation rather than execution-level data.
The 2020–2021 cycle was shaped by three powerful drivers: the post-halving supply reduction, global stimulus, and unprecedented institutional interest. The fintechzoom.com bitcoin price charts from this era showed a steady climb from the 10,000 range toward the all-time high near 69,000.
Key pattern observations:
The plunge from 69,000 to near 15,000 reflected a global macro unwind. The fintechzoom.com bitcoin price today feed during that time repeatedly highlighted themes such as liquidity withdrawal and loss of confidence after major ecosystem failures.
Bear market triggers included:
This cycle exposed a repeating rule: macro tightening overwhelms technical strength.
Bitcoin gradually stabilized between 20,000 and 40,000 before rallying again on expectations of ETF approval. Once regulatory clarity improved, momentum returned. FintechZoom’s reporting during this phase emphasized institutional accumulation and improving liquidity conditions.
Notable drivers of the recovery:
Entering 2025, Bitcoin’s price behavior reflects a maturing asset cycle with slower but more stable appreciation. The fintechzoom.com bitcoin price pages now highlight ETF inflows, supply constraints, and macro policy shifts as dominant drivers.
Key signals shaping the current cycle:
This positions 2025 as a pivotal year for forecasting the 2026 trajectory.
Bitcoin’s past three halving cycles show a consistent pattern: supply reductions tend to shape the next 12 to 18 months of price behavior. When reviewing charts on the fintechzoom.com bitcoin price pages, each halving is followed by a period of stronger long-term holding, reduced exchange balances, and a gradual transition from accumulation to expansion phases.
Important cycle features include:
The coming cycle is shaped by conditions that did not exist in 2020 or 2021. These changes help explain why predictions built on the last five years of data require adjustments.
FintechZoom’s reporting captures these structural shifts, especially on pages such as fintechzoom.com bitcoin price today and fintechzoom.com bitcoin price today news, where macro drivers are often highlighted.
Not every pattern from earlier cycles can be projected forward. Some remain relevant, while others have weakened with market maturation.
Understanding these distinctions helps avoid assuming that past returns will repeat identically. Applying older multipliers without context may lead to unrealistic expectations, which is why cross-referencing multiple data sources, including fintechzoom.com bitcoin price live updates, provides a more grounded approach.
FintechZoom’s simplified price indicators often provide early hints of momentum changes, especially when used alongside technical data from other platforms. Common trend signals include:
Users checking the fintechzoom com bitcoin stock price feed will frequently notice these shifts reflected in both chart summaries and market commentary.
Each scenario is based on a structured weighting framework designed to avoid single-factor bias.
This multi-layer approach supports why we use probability bands rather than fixed-price targets.
This outcome requires a favorable alignment of institutional demand and macro conditions.
FintechZoom’s coverage often highlights institutional behavior, making signals on fintechzoom.com bitcoin price today especially useful for this scenario. Potential risks include regulatory surprises or rapid liquidity tightening that could cap upside momentum.
This scenario represents a balanced post-halving environment with steady but moderated growth.
In this environment, both long-term investors and range traders can benefit from a measured approach. Holding strategies remain effective, while active traders look for repeated zones where support and resistance are clearly defined.
This scenario captures disruptions or macro shocks that undermine the broader uptrend.
FintechZoom’s rapid news updates are especially useful for early warnings in this case. Historical drawdowns show how quickly sentiment can shift when unexpected events emerge.
By combining scenario probabilities with their respective ranges, investors can estimate a blended forward-looking price expectation. This helps define more realistic planning ranges rather than relying on single-target forecasts.
Scenario-based planning helps reduce emotional decision-making during market volatility.
Maintaining a flexible approach supported by ongoing analysis of the fintechzoom.com bitcoin price feed helps investors adapt to new information more effectively.
FintechZoom can support decision-making by combining price snapshots with news-driven context. Unlike platforms focused only on charts or order flow, pages such as fintechzoom.com bitcoin price today and fintechzoom.com bitcoin price live help traders connect price movements with real events. Below are three practical trading approaches that incorporate FintechZoom’s data flow into a broader strategy.
Dollar-cost averaging becomes more effective when aligned with the broader market environment. FintechZoom’s daily commentary offers clues about whether conditions resemble a bullish, neutral, or defensive cycle.
This approach works best when traders combine long-term positioning with updates from fintechzoom.com bitcoin price today news to confirm sentiment shifts.
Bitcoin often trades within identifiable ranges during consolidation phases. FintechZoom’s price feed helps traders track breakouts or reversals around key levels.
Using FintechZoom as a companion to technical platforms helps validate whether moves are news-driven or simply price noise.
FintechZoom excels at identifying catalysts that move markets. Traders who monitor fintechzoom com bitcoin stock price or intraday updates can react faster to events that influence liquidity.
The combination of real-time headlines and simplified price movement summaries allows traders to capture opportunities without relying solely on technical indicators.
Many traders misinterpret short-term moves or overreact to noise. Avoiding the following errors can significantly improve results.
Monitoring fintechzoom.com bitcoin price alongside other datasets helps create a more balanced and disciplined trading process.
CoinZoom is a privately held crypto exchange and its exact valuation is not publicly disclosed in real time. Estimates depend on funding rounds, trading volume, and market share rather than a live quote like the fintechzoom.com bitcoin price pages. For the most accurate picture, investors usually look at recent company announcements, regulatory filings, and market reports instead of assuming a fixed, official “worth.”
The outcome would depend on the exact date and price you bought. As an example, if someone invested 1,000 dollars when Bitcoin traded around 20,000, they would have acquired 0.05 BTC. If, years later, the market price rose to 80,000, that position would be worth about 4,000 dollars. This simple illustration shows why tools such as fintechzoom.com bitcoin price today are often used to backtest past entries and visualize long-term returns, but it is not a guarantee of future performance.
No source, including fintechzoom.com bitcoin price live feeds, can state with certainty what 1 BTC will be worth in 2030. Long-term estimates usually rely on scenarios that consider supply halvings, institutional adoption, regulation, and macro conditions. Some models suggest higher prices if demand continues to grow, while others warn that tighter policy or technological shifts could limit upside. Rather than focusing on a single target, investors often use ranges and revisit their assumptions as new data appears on platforms that track Bitcoin over time.
The fintechzoom.com bitcoin price pages offer a useful blend of real-time data and news context, but the strongest insights come from connecting short-term movements with multi-year patterns. By reviewing Bitcoin’s past five years and applying scenario-based forecasting for 2025–2026, traders can make more informed decisions and respond more effectively to changing market conditions.
Bitcoin is once again approaching a death cross—a technical signal that occurs when the 50-day moving average crosses below the 200-day moving average. Historically, this crossover is seen as a bearish sign, often associated with further downside pressure. But the real question this time is: Will it lead to a bear market or mark a local bottom, as it has in the past year?
In 2023, multiple death crosses formed on Bitcoin's chart. Interestingly, each one coincided with a local bottom, followed by a strong recovery. Traders and analysts began to view the signal less as a harbinger of doom and more as a potential contrarian indicator.
However, zooming out to 2022 tells a different story. That year, a death cross didn't just signal weakness—it triggered a full-blown bear market. Bitcoin plunged from over $40,000 to under $20,000 in the following months. It was a painful reminder that not all technical patterns are created equal, especially when macroeconomic conditions are unstable.
This contrast has left the market on edge. With the current cross forming, the big debate is whether we're looking at another local bottom, or if a deeper correction is looming.
While a death cross alone isn't enough to predict market direction, it should prompt traders to stay cautious and watch key support levels. Other indicators like trading volume, RSI, and macroeconomic signals—including interest rates and ETF flows—will play a role in determining what comes next.
If Bitcoin holds above key levels post-cross, it may again prove to be a buying opportunity. But if support fails, it could signal the start of another prolonged downturn.
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.
Not Logged In
Log in to access more features

FastBull Membership
Not yet
Purchase
Log In
Sign Up